OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

1,368 CYTK shares were withheld to cover taxes or exercise cost (Officer) | OQRO

Home
Insider trades
Cytokinetics
1,368 CYTK shares were withheld to cover taxes or exercise cost (Offic

Insider trades

Insider trade

1,368 CYTK shares were withheld to cover taxes or exercise cost (Officer)

Traded Dec 3, 2025 · Filed Dec 5, 2025

CYTCytokineticsCYTK

1,368
Shares · @ $65.02

Why it stands out

Routine share withholding; mechanical by default.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 3, 2025
Reporting period: Not applicable
Filed with the SEC: Dec 5, 2025

OfficerTax withholding

Context

Classification

tax withholding

Code F — shares delivered to pay exercise price or tax liability

Planned / mechanical clue

Tax mechanics (code F)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001061983-25-000045

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Dec 5, 2025, 9:23 PM UTC

Added to OQRO

Oct 6, 2026, 7:14 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CYTOKINETICS INC

Issuer CIK

1061983

Ticker

CYTK

Reporting person

Andrew Callos

Relationship

Officer

Officer title

EVP, Chief Commercial Officer

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Dec 3, 2025

Transaction code

Shares / units

1,368

Price per share

$65.02

Acquired / disposed

Disposed (D)

Shares owned after

50,660

Ownership form

Direct

Amendment

Footnotes from the filing

Sell to cover transaction for tax withholding upon vesting of Performance Stock Units granted on March 14, 2024 and earned December 2, 2024.

Around the same time

Andrew Callos (EVP, Chief Commercial Officer) sold ~$57K of Cytokinetics

Automatic saleFiled 9mo ago

Andrew CallosEVP, Chief Commercial Officer

Filed 9mo ago

885Shares · @ $37.63

Traded Jan 2 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record

Andrew Callos (EVP, Chief Commercial Officer) sold ~$56K of Cytokinetics

Automatic saleFiled 9mo ago